Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Jan 1;109(1):16-18.
doi: 10.3324/haematol.2023.283468.

Secondary acute myeloid leukemia: time to turn the page

Christian Récher  1
Affiliations
Editorial

Secondary acute myeloid leukemia: time to turn the page

Christian Récher. Haematologica. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Management algorithm for secondary acute myeloid leukemia. alloHCT: allogeneic hematopoietic stem cell transplantation; ASAP: as soon as possible; Conso: consolidation chemotherapy; AML: acute myeloid leukemia; t-AML: therapy-related AML; MR-AML: myelodysplasia-related AML; MRC-AML: AML with myelodysplasia-related changes; MDS: myelodysplastic syndrome; MPN: myeloproliferative neoplasms; AZA-VEN: azacitidine venetoclax; CR/CRi: complete remission/CR with incomplete hematologic recovery.
See this image and copyright information in PMC

Comment on

References

    1. Martínez-Cuadrón D, Megías-Vericat JE, Gil C, et al. Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry. Haematologica. 2024;109(1):115-128. - PMC - PubMed
    1. Lancet JE, Uy GL, Newell LF, et al. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2021;8(7):e481-e491. - PubMed
    1. Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345-1377. - PubMed
    1. Uy GL, Aldoss I, Foster MC, et al. Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. Blood. 2021;137(6):751-762. - PMC - PubMed
    1. Othman J, Meggendorfer M, Tiacci E, et al. Overlapping features of therapy-related and de novo NPM1-mutated AML. Blood. 2023;141(15):1846-1857. - PubMed